TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is placed twelfth on our list. TheFly reported on January 29 that TD Cowen analyst Stacy Ku raised its price target on KALV to $35 from $30 and maintained a Buy rating. The adjustment followed an update to the firm’s financial model ahead of KALV’s upcoming fourth-quarter results. TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results Additionally, earlier o ...